Sangamo Therapeutics (SGMO) Expected to Announce Earnings on Thursday

Posted by Geri Gentry on Jul 30th, 2026

Sangamo Therapeutics (NASDAQ:SGMO – Get Free Report) is anticipated to issue its Q2 2026 resultson Thursday, August 6th. Analysts expect Sangamo Therapeutics to post earnings of ($0.04) per share and revenue of $14.6670 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Sangamo Therapeutics Price Performance

Shares of SGMO opened at $0.07 on Thursday. The company has a market cap of $30.66 million, a PE ratio of -0.17 and a beta of 1.30. The firm has a 50-day moving average of $0.12 and a 200-day moving average of $0.25. Sangamo Therapeutics has a one year low of $0.06 and a one year high of $0.77.

Analyst Ratings Changes

Separately, Zacks Research downgraded shares of Sangamo Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Thursday, April 16th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Reduce” and an average price target of $5.50.

View Our Latest Stock Analysis on Sangamo Therapeutics

Institutional Trading of Sangamo Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in Sangamo Therapeutics by 23.9% during the 3rd quarter. Vanguard Group Inc. now owns 11,615,150 shares of the biopharmaceutical company’s stock worth $7,817,000 after buying an additional 2,240,422 shares during the period. Two Sigma Investments LP grew its position in shares of Sangamo Therapeutics by 182.7% during the 3rd quarter. Two Sigma Investments LP now owns 2,479,186 shares of the biopharmaceutical company’s stock worth $1,669,000 after purchasing an additional 1,602,107 shares in the last quarter. Wasatch Advisors LP grew its holdings in shares of Sangamo Therapeutics by 17.7% during the 2nd quarter. Wasatch Advisors LP now owns 8,084,419 shares of the biopharmaceutical company’s stock worth $4,376,000 after purchasing an additional 1,215,653 shares in the last quarter. Luminus Management LLC increased its holdings in Sangamo Therapeutics by 363.5% in the 4th quarter. Luminus Management LLC now owns 1,158,761 shares of the biopharmaceutical company’s stock valued at $487,000 after buying an additional 908,761 shares during the period. Finally, Geode Capital Management LLC increased its stake in Sangamo Therapeutics by 17.6% in the fourth quarter. Geode Capital Management LLC now owns 3,866,026 shares of the biopharmaceutical company’s stock valued at $1,624,000 after acquiring an additional 579,550 shares during the last quarter. 56.92% of the stock is currently owned by institutional investors.

Sangamo Therapeutics Company Profile

(Get Free Report)

Sangamo Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Brisbane, California, that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology. Founded in 1995, Sangamo pioneered ZFN-based genome editing to precisely alter DNA sequences for the treatment of serious genetic and rare diseases. The company’s platform encompasses in vivo genome editing, ex vivo cell therapy, and genome regulation approaches, with a focus on durable therapeutic effects through permanent genetic modification or sustained gene expression control.

Through its genome editing programs, Sangamo is advancing multiple product candidates into clinical trials for conditions such as hemophilia A and B, mucopolysaccharidosis types I and II, and lysosomal storage disorders.